• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $DGX

    Quest Diagnostics Incorporated

    Subscribe to $DGX
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

    IPO Year:

    Exchange: NYSE

    Website: questdiagnostics.com

    Peers

    $LH

    Recent Analyst Ratings for Quest Diagnostics Incorporated

    DatePrice TargetRatingAnalyst
    8/25/2025$194.00Outperform → Neutral
    Robert W. Baird
    4/2/2025$195.00Buy
    Redburn Atlantic
    3/4/2025$185.00Buy → Neutral
    Citigroup
    1/6/2025$169.00 → $174.00Market Perform → Outperform
    Leerink Partners
    12/17/2024$145.00 → $172.00Equal-Weight → Overweight
    Morgan Stanley
    12/10/2024$175.00 → $185.00Buy
    Jefferies
    10/23/2024$157.00 → $182.00Neutral → Outperform
    Robert W. Baird
    8/28/2024$165.00In-line
    Evercore ISI
    7/10/2024$145.00 → $165.00Neutral → Buy
    Citigroup
    2/26/2024$135.00Market Perform
    Leerink Partners
    See more ratings

    Quest Diagnostics Incorporated Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Quest Diagnostics downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Quest Diagnostics from Outperform to Neutral and set a new price target of $194.00

    8/25/25 8:10:20 AM ET
    $DGX
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Quest Diagnostics with a new price target

    Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00

    4/2/25 8:51:11 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics downgraded by Citigroup with a new price target

    Citigroup downgraded Quest Diagnostics from Buy to Neutral and set a new price target of $185.00

    3/4/25 7:20:57 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Quest Diagnostics from Market Perform to Outperform and set a new price target of $174.00 from $169.00 previously

    1/6/25 7:49:06 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Quest Diagnostics from Equal-Weight to Overweight and set a new price target of $172.00 from $145.00 previously

    12/17/24 7:42:14 AM ET
    $DGX
    Medical Specialities
    Health Care

    Jefferies resumed coverage on Quest Diagnostics with a new price target

    Jefferies resumed coverage of Quest Diagnostics with a rating of Buy and set a new price target of $185.00 from $175.00 previously

    12/10/24 6:50:41 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Quest Diagnostics from Neutral to Outperform and set a new price target of $182.00 from $157.00 previously

    10/23/24 6:23:16 AM ET
    $DGX
    Medical Specialities
    Health Care

    Evercore ISI resumed coverage on Quest Diagnostics with a new price target

    Evercore ISI resumed coverage of Quest Diagnostics with a rating of In-line and set a new price target of $165.00

    8/28/24 7:40:37 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics upgraded by Citigroup with a new price target

    Citigroup upgraded Quest Diagnostics from Neutral to Buy and set a new price target of $165.00 from $145.00 previously

    7/10/24 7:29:39 AM ET
    $DGX
    Medical Specialities
    Health Care

    Leerink Partners initiated coverage on Quest Diagnostics with a new price target

    Leerink Partners initiated coverage of Quest Diagnostics with a rating of Market Perform and set a new price target of $135.00

    2/26/24 7:28:32 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Incorporated Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP & General Counsel Prevoznik Michael E exercised 28,463 shares at a strike of $103.57 and sold $5,326,042 worth of shares (28,463 units at $187.12) (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    9/25/25 4:39:11 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP for Diagnostic Services Plewman Patrick sold $365,375 worth of shares (1,975 units at $185.00), decreasing direct ownership by 11% to 15,269 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    8/25/25 4:27:59 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP for Diagnostic Services Plewman Patrick exercised 4,532 shares at a strike of $112.17 and sold $829,356 worth of shares (4,532 units at $183.00) (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    8/21/25 4:34:05 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP for Diagnostic Services Plewman Patrick sold $355,500 worth of shares (1,975 units at $180.00), decreasing direct ownership by 10% to 17,244 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    8/19/25 4:47:13 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP, Clinical Solutions Kuppusamy Karthik covered exercise/tax liability with 123 shares, decreasing direct ownership by 1% to 8,338 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    8/15/25 5:25:57 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP for Diagnostic Services Plewman Patrick sold $968,625 worth of shares (5,535 units at $175.00) and exercised 3,560 shares at a strike of $86.63, decreasing direct ownership by 9% to 19,219 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    8/8/25 4:40:39 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP, Clinical Solutions Kuppusamy Karthik exercised 8,269 shares at a strike of $102.77 and sold $1,759,931 worth of shares (10,479 units at $167.95), decreasing direct ownership by 21% to 8,450 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    8/1/25 4:37:46 PM ET
    $DGX
    Medical Specialities
    Health Care

    Executive Vice President & CFO Samad Sam increased direct ownership by 0.28% to 25,673 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    7/25/25 4:29:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP for Diagnostic Services Plewman Patrick increased direct ownership by 0.38% to 21,185 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    7/25/25 4:28:32 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP, Clinical Solutions Kuppusamy Karthik increased direct ownership by 0.25% to 10,660 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    7/25/25 4:28:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Incorporated SEC Filings

    View All

    SEC Form 144 filed by Quest Diagnostics Incorporated

    144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    9/26/25 4:12:08 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 144 filed by Quest Diagnostics Incorporated

    144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    9/23/25 4:14:25 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 144 filed by Quest Diagnostics Incorporated

    144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    8/21/25 12:10:39 PM ET
    $DGX
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Quest Diagnostics Incorporated

    SCHEDULE 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    8/14/25 1:07:20 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Quest Diagnostics Incorporated

    10-Q - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    7/23/25 4:25:08 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    7/22/25 6:48:39 AM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 11-K filed by Quest Diagnostics Incorporated

    11-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    6/20/25 4:20:51 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form S-3ASR filed by Quest Diagnostics Incorporated

    S-3ASR - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    6/20/25 4:08:24 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    5/22/25 6:28:25 AM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SCHEDULE 13G filed by Quest Diagnostics Incorporated

    SCHEDULE 13G - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    5/14/25 10:45:25 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Incorporated Press Releases

    Fastest customizable press release news feed in the world

    View All

    WHOOP Launches Clinician-Reviewed Advanced Labs, Unlocking a Comprehensive View of Human Health

    Over 350,000 members have joined the waitlist since May, underscoring the excitement for one product that can pair blood biomarkers with 24/7 wearable data WHOOP, the human performance company, today announced the launch of WHOOP Advanced Labs, a groundbreaking new feature that combines blood testing with continuous wearable data to deliver a complete picture of health. Members can upload past bloodwork results or schedule the company's curated Advanced Labs panel, which tests an extensive set of biomarkers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250930178710/en/WHOOP Launches Clinician-Reviewed Advanced Labs, Unlockin

    9/30/25 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025

    SECAUCUS, N.J., Sept. 25, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report third quarter 2025 financial results on Tuesday, October 21, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted

    9/25/25 10:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States

    Collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest's vast network Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, and Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced a broad strategic collaboration to make Guardant's Shield™ blood-based screening test available to physicians and patients served by Quest in the United States. Shield is the first and only blood test to receive full FDA approval as a primary screening option for colorectal cancer in average-risk adults aged 45 and older. Through a multi-year agreement, Quest's provider clients that

    9/24/25 8:05:00 AM ET
    $DGX
    $GH
    Medical Specialities
    Health Care

    Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration

    With the most comprehensive Epic integration by a laboratory provider, collaboration will streamline and strengthen the customer experience for health systems, hospitals, independent providers and their patients SECAUCUS, N.J., Sept. 23, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX) and Epic today announced a first-of-its-kind collaboration designed to streamline and improve experiences for healthcare providers and patients that engage Quest for laboratory testing in the United States. Epic will work with Quest to deliver a suite of technologies and services to act as the

    9/23/25 7:07:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer

    SECAUCUS, N.J. and NEW BRUNSWICK, N.J., Sept. 22, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE:DGX) company, today announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD®, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) test, to help optimize postoperative therapy decisions in patients with stage II/III non-small cell lung cancer (NSCLC). Rutgers Cancer Institute together with RWJBarnabas Health is the state's only National Cancer Institute-designated Comprehensive Cancer Center. 

    9/22/25 8:07:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    WHOOP to Bring Clinical Lab Testing from Quest Diagnostics to the WHOOP App

    Implementation will enable users to purchase, schedule appointments for testing, and receive results of lab tests performed by Quest within the WHOOP app, supporting access to deeper health and performance insights. WHOOP, the human performance company, today announced that Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, will be the U.S. lab provider for WHOOP Advanced Labs, a new WHOOP feature that provides laboratory insights supporting health and performance. The offering will provide the option to purchase Quest's clinical laboratory testing, schedule an appointment for testing, and receive test results within the WHOOP app. WHOOP Advanced Labs is

    9/18/25 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics to Speak at the Jefferies Healthcare Services Conference

    SECAUCUS, N.J., Sept. 15, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during the Jefferies Healthcare Services Conference in Nashville on Monday, September 29, 2025, at 4:35 p.m. Eastern Time. The fireside chat and Q&A session will be webcast live during the conference on the company's investor relations page, which can be accessed a

    9/15/25 6:21:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering

    New Service Empowers Clinicians with Personalized Insights from Coriell Life Sciences to Optimize Prescribing Across Specialties SECAUCUS, N.J., Sept. 4, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced an advanced pharmacogenomic (PGx) laboratory test service designed to help providers understand the patient's individual genetic response to select drug therapies. This innovative offering aims to help providers determine appropriate medication on selection and dosing. It utilizes PGx information across a wide range of medical specialties including psychiatry, neurology, cardiology, oncology, rheumatology, pain manageme

    9/4/25 9:32:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index

    Majority of fentanyl positives also contain other drugs, with co-positivity with marijuana doubling since 2020 SECAUCUS, N.J., Sept. 2, 2025 /PRNewswire/ -- The percentage of employees in the general U.S. workforce testing positive for fentanyl in random drug tests far exceeded those in pre-employment testing, according to the 2025 Quest Diagnostics Drug Testing Index™ from Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services. The new report reveals changing patterns of drug use by the nation's workforce. While the analysis of more than 8 million

    9/2/25 6:27:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Corewell Health and Quest Diagnostics to Enter into Joint Venture Providing Enhanced Laboratory Services in Michigan

    Parties to build state-of-the-art laboratory in Southfield to serve physicians and patients across the state Quest will also manage Corewell Health's 21 hospital labs SOUTHFIELD, Mich. and GRAND RAPIDS, Mich. and SECAUCUS, N.J., Aug. 26, 2025 /PRNewswire/ -- Corewell Health and Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, have signed a definitive agreement to enter into a joint venture to expand access to innovative, quality and affordable laboratory services in Michigan. The joint venture, Diagnostic Lab of Michigan, LLC, will be based at a state-of-the-art laboratory facility at the Corewell Health Southfield Center in Southfield, Michigan. The fu

    8/26/25 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Incorporated Leadership Updates

    Live Leadership Updates

    View All

    Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health

    Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh

    1/17/24 8:58:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Board of Directors Elects James E. Davis Chairman of the Board

    SECAUCUS, N.J., March 3, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors elected James E. Davis, the company's Chief Executive Officer and President, to serve in the additional position of Chairman of the Board of Directors, effective April 1, 2023. "The Board carefully considered our governance structure and determined that combining the roles of Chairman and CEO under Jim Davis's leadership is in the best interest of shareholders to successfully continue to execute

    3/3/23 4:30:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quotient Limited Announces Appointment of Chief Financial Officer

    JERSEY, Channel Islands, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Ali Kiboro as the Company's Chief Financial Officer (CFO). Mr. Kiboro will assume the responsibilities of CFO on November 1st, 2021, replacing Mr. Peter Buhler who will support the Company during the transitional phase, as needed, before leaving Quotient Limited at year-end. "I am delighted to welcome Ali to the Executive team at this exciting time in our Company's evolution. He brings over 20 years of experience in global finance and has been a key driver of operational excellence in a career spanning healthcare services and manufacturing. I w

    10/12/21 8:45:00 AM ET
    $DGX
    $QTNT
    Medical Specialities
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    WNS Announces Addition of Tim Main to Board of Directors

    WNS (Holdings) Limited (NYSE:WNS), a leading provider of global Business Process Management (BPM) solutions, today announced the appointment of Timothy L. Main to the company's Board of Directors effective June 1, 2021. Tim has spent his entire career in a B2B services/outsourcing environment, including more than 25 years with Jabil, Inc. (NYSE:JBL), a leading provider of manufacturing services with a global operational footprint. At Jabil, Tim worked his way from a Production Control Manager position to eventually serve as President, Chief Executive Officer, and Chairman of the Board. During his 13-year tenure as Chief Executive Officer of Jabil, he led the company's transformation and gro

    5/18/21 4:15:00 PM ET
    $WNS
    $DGX
    $JBL
    Real Estate
    Medical Specialities
    Health Care
    Electrical Products

    Quest Diagnostics Incorporated Financials

    Live finance-specific insights

    View All

    Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025

    SECAUCUS, N.J., Sept. 25, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report third quarter 2025 financial results on Tuesday, October 21, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted

    9/25/25 10:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Declares Quarterly Cash Dividend

    SECAUCUS, N.J., Aug. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on October 20, 2025 to shareholders of record of Quest Diagnostics common stock on October 3, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to ta

    8/13/25 6:35:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

    Second quarter revenues of $2.76 billion, up 15.2% from 2024Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5% from 2024Year-to-date cash provided by operations of $858 million, up 67.1% from 2024Full year 2025 reported diluted EPS now expected to be between $8.60 and $8.80; and adjusted diluted EPS is expected to be between $9.63 and $9.83SECAUCUS, N.J., July 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2025.

    7/22/25 6:47:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025

    SECAUCUS, N.J., June 23, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2025 financial results on Tuesday, July 22, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.Q

    6/23/25 10:52:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Declares Quarterly Cash Dividend

    SECAUCUS, N.J., May 14, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025 to shareholders of record of Quest Diagnostics common stock on July 7, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take acti

    5/14/25 6:17:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025

    First quarter revenues of $2.65 billion, up 12.1% from 2024First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024Full year 2025 reported diluted EPS now expected to be between $8.62 and $8.87; and adjusted diluted EPS is expected to remain between $9.55 and $9.80SECAUCUS, N.J., April 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025. "In the fir

    4/22/25 6:43:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics to Release First Quarter 2025 Financial Results on April 22, 2025

    SECAUCUS, N.J., April 1, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2025 financial results on Tuesday, April 22, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.Q

    4/1/25 4:23:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Guidance for Full Year 2025; Increases Quarterly Dividend 6.7% to $0.80 Per Share

    Fourth quarter revenues of $2.62 billion, up 14.5% from 2023Fourth quarter reported diluted earnings per share ("EPS") of $1.95, up 14.7% from 2023; and adjusted diluted EPS of $2.23, up 3.7% from 2023Full year revenues of $9.87 billion, up 6.7% from 2023Full year reported diluted EPS of $7.69, up 2.7% from 2023; and adjusted diluted EPS of $8.93, up 2.5% from 2023Full year 2025 reported diluted EPS expected to be between $8.34 and $8.59; and adjusted diluted EPS expected to be between $9.55 and $9.80SECAUCUS, N.J., Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, announced today financial results for the fourth q

    1/30/25 6:45:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics to Release Fourth Quarter and Full Year 2024 Financial Results on January 30, 2025

    SECAUCUS, N.J., Jan. 2, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leader in diagnostic information services, announced that it will report fourth quarter and full year 2024 financial results on Thursday, January 30, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be

    1/2/25 11:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Declares Quarterly Cash Dividend

    SECAUCUS, N.J., Nov. 12, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on January 29, 2025 to shareholders of record of Quest Diagnostics common stock on January 14, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to t

    11/12/24 5:57:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Incorporated Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/13/24 5:12:21 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    1/25/24 12:16:40 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/7/23 1:25:52 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Quest Diagnostics Incorporated

    SC 13G - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/10/22 3:52:05 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/10/22 8:32:51 AM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/10/21 11:40:12 AM ET
    $DGX
    Medical Specialities
    Health Care